Expression level of NEAT1 differentiates benign and malignant thyroid nodules by regulating NEAT1/miR‑9/PTEN and NEAT1/miR‑124/PDCD6 signalling

Zhao,Li; Zhou,Na; Zhao,Ping

doi:10.3892/ijmm.2020.4721

Expression level of NEAT1 differentiates benign and malignant thyroid nodules by regulating NEAT1/miR‑9/PTEN and NEAT1/miR‑124/PDCD6 signalling

Authors:
- Li Zhao
- Na Zhou
- Ping Zhao
View Affiliations

Affiliations: Department of Ultrasound, Southwest University Hospital, Chongqing 400715, P.R. China, Department of Abdominal Ultrasound, Xinjiang Autonomous Region Hospital of Traditional Chinese Medicine, Urumchi, Xinjiang 830000, P.R. China, Department of Ultrasound, Shangluo Central Hospital, Shangluo, Shaanxi 726000, P.R. China
Published online on: September 4, 2020 https://doi.org/10.3892/ijmm.2020.4721
Pages: 1661-1670
Copyright: © Zhao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The incidence of thyroid nodules has been increasing worldwide; however, there are currently no feasible and robust methods to differentiate malignant thyroid nodules from benign thyroid nodules. The present study aimed to establish a practical method to determine the malignancy of thyroid nodules. Reverse transcription‑quantitative PCR and western blot analyses were performed to compare the levels of long non‑coding RNA nuclear enriched abundant transcript 1 (NEAT1), microRNA (miR)‑9, miR‑124, PTEN and programmed cell death protein 6 (PDCD6) in the peripheral blood and thyroid tissue samples between patients with malignant and benign thyroid nodules. Additionally, a regulatory relationship between NEAT1, miR‑124, miR‑9, PTEN and PDCD6 was established in the present study. The diagnostic value of NEAT1, miR‑124 and miR‑9 was determined using a ROC analysis. The expression levels of NEAT1, PTEN and PDCD6 in peripheral blood and thyroid tissue samples collected from the benign group were higher compared with those in the malignant group, whereas the expression levels of miR‑124 and miR‑9 were lower in the benign group. In the peripheral blood, NEAT1 expression exhibited an area under the curve (AUC) value of 0.8546, whereas miR‑124 and miR‑9 expression had AUC values of 0.7657 and 0.7019, respectively. In the thyroid tissue, NEAT1, miR‑124, and miR‑9 had AUC values of 0.9304, 0.8221 and 0.7757, respectively. Additionally, miR‑9 and miR‑124 expression levels in BCPaP and SW579 cells was decreased after transfection with a NEAT1 expression vector compared with those in cells transfected with the control vector, whereas the expression of PTEN and PDCD6 was upregulated. By contrast, transfection with short hairpin RNA targeting NEAT1 notably increased the expression of miR‑9 and miR‑124 while downregulating the expression of PTEN and PDCD6 compared with that in the control cells. In conclusion, the results of the present study demonstrated that the dysregulation of NEAT1 expression may be used to differentiate benign and malignant thyroid nodules.

View Figures

View References

1	Shaheen Z, BenHamed NA and Elhamdani RM: MON-436 cribriform-morular variant of papillary thyroid carcinoma: A case report. J Endocr Soc. 4(Suppl 1): MON-4362020. View Article : Google Scholar :
2	Frates MC, Benson CB, Charboneau JW, Cibas ES, Clark OH, Coleman BG, Cronan JJ, Doubilet PM, Evans DB, Goellner JR, et al: Management of thyroid nodules detected at US: Society of radiologists in ultrasound consensus conference statement. Ultrasound Q. 22:231–240. 2006. View Article : Google Scholar : PubMed/NCBI
3	Papini E, Guglielmi R, Bianchini A, Crescenzi A, Taccogna S, Nardi F, Panunzi C, Rinaldi R, Toscano V and Pacella CM: Risk of malignancy in nonpalpable thyroid nodules: Predictive value of ultrasound and color-Doppler features. J Clin Endocrinol Metab. 87:1941–1946. 2002. View Article : Google Scholar : PubMed/NCBI
4	Frates MC, Benson CB, Doubilet PM, Kunreuther E, Contreras M, Cibas ES, Orcutt J, Moore FD Jr, Larsen PR, Marqusee E and Alexander EK: Prevalence and distribution of carcinoma in patients with solitary and multiple thyroid nodules on sonography. J Clin Endocrinol Metab. 91:3411–3417. 2006. View Article : Google Scholar : PubMed/NCBI
5	Yassa L, Cibas ES, Benson CB, Frates MC, Doubilet PM, Gawande AA, Moore FD Jr, Kim BW, Nosé V, Marqusee E, et al: Long-term assessment of a multidisciplinary approach to thyroid nodule diagnostic evaluation. Cancer. 111:508–516. 2007. View Article : Google Scholar : PubMed/NCBI
6	Haugen BR: 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: What is new and what has changed? Cancer. 123:372–381. 2017. View Article : Google Scholar
7	Wang CC, Friedman L, Kennedy GC, Wang H, Kebebew E, Steward DL, Zeiger MA, Westra WH, Wang Y, Khanafshar E, et al: A large multicenter correlation study of thyroid nodule cytopathology and histopathology. Thyroid. 21:243–251. 2011. View Article : Google Scholar
8	Maher B: ENCODE: The human encyclopedia. Nature. 489:46–48. 2012. View Article : Google Scholar : PubMed/NCBI
9	Dianatpour A and Ghafouri-Fard S: Long non-coding RNA expression intersecting cancer and spermatogenesis: A systematic review. Asian Pac J Cancer Prev. 18:2601–2610. 2017.PubMed/NCBI
10	He JH, Han ZP and Li YG: Association between long non-coding RNA and human rare diseases (Review). Biomed Rep. 2:19–23. 2014. View Article : Google Scholar : PubMed/NCBI
11	Maruyama R, Suzuki H, Yamamoto E, Imai K and Shinomura Y: Emerging links between epigenetic alterations and dysregulation of noncoding RNAs in cancer. Tumour Biol. 33:277–285. 2012. View Article : Google Scholar : PubMed/NCBI
12	Mercer TR, Dinger ME and Mattick JS: Long non-coding RNAs: Insights into functions. Nat Rev Genet. 10:155–159. 2009. View Article : Google Scholar : PubMed/NCBI
13	Hu YC, Wang AM, Lu JK, Cen R and Liu LL: Long noncoding RNA HOXD-AS1 regulates proliferation of cervical cancer cells by activating Ras/ERK signaling pathway. Eur Rev Med Pharmacol Sci. 21:5049–5055. 2017.PubMed/NCBI
14	Adriaens C and Marine JC: NEAT1-containing paraspeckles: Central hubs in stress response and tumor formation. Cell Cycle. 16:137–138. 2017. View Article : Google Scholar :
15	Choudhry H and Mole DR: Hypoxic regulation of the noncoding genome and NEAT1. Brief Funct Genomics. 15:174–185. 2016. View Article : Google Scholar :
16	Xie Q, Lin S, Zheng M, Cai Q and Tu Y: Long noncoding RNA NEAT1 promotes the growth of cervical cancer cells via sponging miR-9-5p. Biochem Cell Biol. 97:100–108. 2019. View Article : Google Scholar
17	Ma Y, Liu L, Yan F, Wei W, Deng J and Sun J: Enhanced expression of long non-coding RNA NEAT1 is associated with the progression of gastric adenocarcinomas. World J Surg Oncol. 14:412016. View Article : Google Scholar : PubMed/NCBI
18	Gao C, Zhang J, Wang Q and Ren C: Overexpression of lncRNA NEAT1 mitigates multidrug resistance by inhibiting ABCG2 in leukemia. Oncol Lett. 12:1051–1057. 2016. View Article : Google Scholar : PubMed/NCBI
19	Lu E, Su J, Zeng W and Zhang C: Enhanced miR-9 promotes laryngocarcinoma cell survival via down-regulating PTEN. Biomed Pharmacother. 84:608–613. 2016. View Article : Google Scholar : PubMed/NCBI
20	Cheng N and Guo Y: Long noncoding RNA NEAT1 promotes nasopharyngeal carcinoma progression through regulation of miR-124/NF-κB pathway. Onco Targets Ther. 10:5843–5853. 2017. View Article : Google Scholar :
21	Zhang L, Chen X, Liu B and Han J: MicroRNA-124-3p directly targets PDCD6 to inhibit metastasis in breast cancer. Oncol Lett. 15:984–990. 2018.PubMed/NCBI
22	Yu S, Liu X, Zhang Y, Li J, Chen S, Zheng H, Reng R, Zhang C, Chen J and Chen L: Circulating microRNA124-3p, microRNA9-3p and microRNA196b-5p may be potential signatures for differential diagnosis of thyroid nodules. Oncotarget. 7:84165–84177. 2016. View Article : Google Scholar : PubMed/NCBI
23	Lei H, Gao Y and Xu X: LncRNA TUG1 influences papillary thyroid cancer cell proliferation, migration and EMT formation through targeting miR-145. Acta Biochim Biophys Sin (Shanghai). 49:588–597. 2017. View Article : Google Scholar
24	Bartolazzi A, Sciacchitano S and D'Alessandria C: Galectin-3: The impact on the clinical management of patients with thyroid nodules and future perspectives. Int J Mol Sci. 19:4452018. View Article : Google Scholar :
25	Zhang YZ, Xu T, Gong HY, Li CY, Ye XH, Lin HJ, Shen MP, Duan Y, Yang T and Wu XH: Application of high-resolution ultrasound, real-time elastography, and contrast-enhanced ultrasound in differentiating solid thyroid nodules. Medicine (Baltimore). 95:e53292016. View Article : Google Scholar
26	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
27	Morselli E, Galluzzi L, Kepp O, Vicencio JM, Criollo A, Maiuri MC and Kroemer G: Anti- and pro-tumor functions of autophagy. Biochim Biophys Acta. 1793:1524–1532. 2009. View Article : Google Scholar : PubMed/NCBI
28	Su CH, Chen LJ, Liao JF and Cheng JT: Increase of phosphatase and tensin homolog by silymarin to inhibit human pharynx squamous cancer. J Med Food. 16:778–784. 2013. View Article : Google Scholar : PubMed/NCBI
29	Eng C: PTEN: One gene, many syndromes. Hum Mutat. 22:183–198. 2003. View Article : Google Scholar : PubMed/NCBI
30	Hobert JA, Embacher R, Mester JL, Frazier TW II and Eng C: Biochemical screening and PTEN mutation analysis in individuals with autism spectrum disorders and macrocephaly. Eur J Hum Genet. 22:273–276. 2014. View Article : Google Scholar :
31	Vito P, Lacanà E and D'Adamio L: Interfering with apoptosis: Ca(2+)-binding protein ALG-2 and Alzheimer's disease gene ALG-3. Science. 271:521–525. 1996. View Article : Google Scholar : PubMed/NCBI
32	Maki M, Narayana SV and Hitomi K: A growing family of the Ca²⁺-binding proteins with five EF-hand motifs. Biochem J. 328:718–720. 1997.
33	Ohkouchi S, Nishio K, Maeda M, Hitomi K, Adachi H and Maki M: Identification and characterization of two penta-EF-hand Ca(2+)-binding proteins in Dictyostelium discoideum. J Biochem. 130:207–215. 2001. View Article : Google Scholar : PubMed/NCBI
34	Su D, Xu H, Feng J, Gao Y, Gu L, Ying L, Katsaros D, Yu H, Xu S and Qi M: PDCD6 is an independent predictor of progression free survival in epithelial ovarian cancer. J Transl Med. 10:312012. View Article : Google Scholar : PubMed/NCBI
35	la Cour JM, Høj BR, Mollerup J, Simon R, Sauter G and Berchtold MW: The apoptosis linked gene ALG-2 is dysregu-lated in tumors of various origin and contributes to cancer cell viability. Mol Oncol. 1:431–439. 2008. View Article : Google Scholar
36	Jiang X, Zhou Y, Sun AJ and Xue JL: NEAT1 contributes to breast cancer progression through modulating miR-448 and ZEB1. J Cell Physiol. 233:8558–8566. 2018. View Article : Google Scholar : PubMed/NCBI
37	Zhao D, Zhang Y, Wang N and Yu N: NEAT1 negatively regulates miR-218 expression and promotes breast cancer progression. Cancer Biomark. 20:247–254. 2017. View Article : Google Scholar : PubMed/NCBI
38	Han D, Wang J and Cheng G: LncRNA NEAT1 enhances the radio-resistance of cervical cancer via miR-193b-3p/CCND1 axis. Oncotarget. 9:2395–2409. 2017. View Article : Google Scholar
39	Souquere S, Beauclair G, Harper F, Fox A and Pierron G: Highly ordered spatial organization of the structural long noncoding NEAT1 RNAs within paraspeckle nuclear bodies. Mol Biol Cell. 21:4020–4027. 2010. View Article : Google Scholar : PubMed/NCBI
40	Yu X, Li Z, Zheng H, Chan MT and Wu WK: NEAT1: A novel cancer-related long non-coding RNA. Cell Prolif. 50:e123292017. View Article : Google Scholar
41	Chai Y, Liu J, Zhang Z and Liu L: HuR-regulated lncRNA NEAT1 stability in tumorigenesis and progression of ovarian cancer. Cancer Med. 5:1588–1598. 2016. View Article : Google Scholar : PubMed/NCBI
42	Idogawa M, Ohashi T, Sasaki Y, Nakase H and Tokino T: Long non-coding RNA NEAT1 is a transcriptional target of p53 and modulates p53-induced transactivation and tumor-suppressor function. Int J Cancer. 140:2785–2791. 2017. View Article : Google Scholar : PubMed/NCBI